Enhancing the Effects of Adolescent Alcohol Treatment With Acetyl-L-Carnitine
Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effects of acetyl-L-carnitine (ALCAR),
3 g daily, and matched placebo on alcohol cue-elicited alcohol craving during a human
laboratory paradigm after 4 weeks of daily dosing among participants ages 14-20 with alcohol
use disorder (AUD) as confirmed by the Diagnostic and Statistical Manual of Mental Disorders
- Fifth Edition (DSM-5™) and who report at least mild depressive symptoms on the Beck
Depression Inventory-II. Secondary objectives include evaluation of ALCAR (3g/day) and
matched placebo on alcohol craving and use, subjective effects of alcohol consumption, mood,
sleep, alcohol use negative consequences, study retention, and safety and tolerability.
Phase:
Phase 1
Details
Lead Sponsor:
Brown University
Collaborators:
Colorado State University National Institute on Alcohol Abuse and Alcoholism (NIAAA) Rhode Island Hospital